In addition, VTP50496 and Selinexor cooperatively suppress the growth of NPM1::CCDC28A cells, providing a rational basis for clinical testing of the XPO1/menin co-targeting approach for NPM1-fusion AML. This evidence concerns the gene MEN1 and acute myeloid leukemia.